SCHEMBL25520028

SCHEMBL25520028

CCCC(CC)NOC(=O)Nc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.44
ALDH1A1 P00352 6/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPK1 P28482 2/20 0.44
LMNA P02545 3/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 2/20 0.41
PKM P14618 1/20 0.41
NPC1 O15118 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
KLK7 P49862 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25525421 0.91 RAB9A (0.49) RAB9AALDH1A1SMN1; SMN2GAAHTT
SCHEMBL25522603 0.84 POLB (0.47) RAB9AALDH1A1SMN1; SMN2GAAHTT
SCHEMBL25524857 0.80 RAB9A (0.48) RAB9AALDH1A1SMN1; SMN2GAAHTT
SCHEMBL25523405 0.80 RAB9A (0.48) RAB9AALDH1A1SMN1; SMN2GAAHTT
SCHEMBL20862403 0.77 TAS1R3 (0.57) RAB9AALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL25518860 0.76 SMN1; SMN2 (0.53) RAB9AALDH1A1SMN1; SMN2GAAHTT
SCHEMBL22459216 0.76 CTSK (0.48) RAB9AALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL415619 0.73 GAA (0.57) RAB9AALDH1A1SMN1; SMN2GAAHTT
SCHEMBL25522587 0.73 RAB9A (0.53) RAB9AALDH1A1SMN1; SMN2GAAHTT
SCHEMBL9707304 0.71 NAPRT (0.61) RAB9AALDH1A1SMN1; SMN2GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF HDAC6, PSMG3, PSMB2 RAB9A 2211/4885ALDH1A1 2269/4885SMN1; SMN2 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.